Aberrant DOT1L expression or enzyme activity has been found also in other non-hematologic cancers, including lung, melanoma, neuroblastoma, liver, and head and neck squamous cell carcinomas (HNSCCs). This evidence concerns the gene DOT1L and neuroblastoma.